Ocular Therapeutix (FRA:0OT) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0OT Ocular Therapeutix Inc FRA:0OT
51 GF Score
Price €7.70
GF Value €3.86
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Ocular Therapeutix Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:0OT
51GF Score
Ocular Therapeutix Inc FRA:0OT
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ocular Therapeutix (FRA:0OT) Overvalued in 2026?

Based on GuruFocus' analysis, Ocular Therapeutix stock appears to be overvalued. The current stock price of €7.70 is trading 99.5% above its estimated GF Value™ of €3.86. GuruFocus considers Ocular Therapeutix to be Significantly Overvalued.

Key valuation signals for FRA:0OT:

  • Dividends Received:
  • GF Value™: €3.86 vs. price of €7.70 (99.5% above fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the FRA:0OT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ocular Therapeutix Business Description

Other Exchanges OCUL:USA0OT:Germany
Address 15 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
51GF Score

Get the complete analysis for FRA:0OT

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.70
Price
€3.86
GF Value